Strategic Internal Review initiated for treasury diversification through a prospective digital asset subsidiary — no entity formed, no capital committedLA PALMA, Calif., July 25, 2025 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (NASDAQ: LIMN), a preclinical-stage biopharmaceutical company dedicated to the development of targeted cancer immunotherapies, today announced that its Board of Directors and executive team have formally initiated a strategic review to explore the potential formation of a dedicated di ...

The European Commission's Approval of Zenrelia reinforces safety and efficacy and further expands opportunities to treat itchy dogs around the world Launch to begin immediately with product in market before the end of Q3 2025GREENFIELD, Ind., July 24, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) announced today that Zenrelia™ (ilunocitinib) has received approval by the European Commission.This approval by the EU reinforces Zenrelia's status as a highly effective, convenient, and safe ...

Core Insights - Mattel experienced a 16% year-over-year decline in sales in North America, which was partially offset by a 7% increase in international sales, leading to an overall net sales decline of 6% year-over-year in the second quarter [2][3] Group 1: Sales Performance - The U.S. sales were significantly impacted by retailers adjusting their order patterns due to uncertainties surrounding tariffs [4] - The company is focusing on optimizing for profitable growth and seeking supply chain efficiencies, along with making pricing adjustments in the U.S. [5] Group 2: Strategic Initiatives - Mattel is working on capturing the full value of its intellectual property, including launching the first UNO Social Club and scaling its film production pipeline [6] - The company has partnered with OpenAI to integrate artificial intelligence into its iconic toys, aiming to enhance brand engagement and innovation [7] Group 3: Future Outlook - Mattel anticipates a return to growth in net sales but has lowered its guidance for fiscal year 2025, now expecting a rise of 1% to 3% compared to the previous guidance of 2% to 3% [7] - The company is embracing technology and collaborating with partners to position itself for long-term success [8]

Mattel (MAT) Q2 2025 Earnings Call July 23, 2025 05:00 PM ET Company ParticipantsJenn Kettnich - VP & Head of IRYnon Kreiz - Chairman, CEO & DirectorPaul Ruh - CFOKylie Cohu - Consumer Equity ResearchStephen Laszczyk - Vice PresidentArpine Kocharian - Managing DirectorAlexander Perry - Director - Equity ResearchConference Call ParticipantsEric Handler - MD & Senior Research AnalystMegan Clapp - Equity Research AnalystChristopher Horvers - Senior AnalystJames Hardiman - Director - Leisure and Travel AnalystO ...

Mattel (MAT) Q2 2025 Earnings Call July 23, 2025 05:00 PM ET Speaker0Thank you for standing by. My name is Kate, and I will be your conference operator today. At this time, I would like to welcome everyone to Mattel Inc. Second Quarter twenty twenty five Earnings Conference Call. All lines have been placed on mute to prevent any background noise.After the speakers' remarks, there will be a question and answer session. Thank you. I would now like to turn the call over to Jen Kittnick, VP of Investor Relation ...

前两天昆仑万维的朋友来找我吃饭。 跟我说，他们的新音乐模型Mureka v7马上要上线了，他们觉得质量能跟Suno 4.5打一打，而且也是国内为数不多的AI音乐产品，问我要不要一拍即合一 下。 当时吃着饭呢，我筷子抖了一下。 我说AI音乐我现在写的真的非常少，上次写完suno 3.5我就没写了，我都快一年没提过AI音乐了，我感觉拍不了啊。 他们说，你放屁。 然后掏了这篇文章给我看。 说，你前一段时间不刚提吗。 我说...啊。。。 然后他们就非常快速当场的给我开了Mureka v7新音乐模型的内测，开了会员，给了400积分，说，你先试试？ 我说行，那试试吧。。。 当天晚上回家后，我看着那个音乐生成的界面，我脑子里真的一团浆糊。 真的，感觉这块的知识，完全丢干净了。 我好像不知道该写一首什么样的歌，或者，该怎么创作一首AI的音乐了。 就这么浆糊着半个小时，我说算了，休息一下吧，于是打开了最近天天摸鱼的时候，最爱看的小说：《十日终焉》 看到即将全员反攻列车，七十年的布局要进入最高潮的时候。 我突然有了灵感。 我就想做一首，《十日终焉》的主题曲。 但是理想很丰满，但是吧，真到上手的时候，发现犯了难了。 我好像，这一年 ...

Preclinical-stage biotech company explores digital asset treasury opportunities to enhance capital efficiency while maintaining core focus on immunotherapy innovationLA PALMA, Calif., July 22, 2025 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (NASDAQ: LIMN), a preclinical-stage biopharmaceutical company dedicated to the development of targeted cancer immunotherapies, today announced that it has initiated a strategic review to evaluate the potential inclusion of regulated digital asset strategies as part of it ...

Since the last time I wrote about immunology treatment provider AbbVie Inc. (NYSE: ABBV ) in April, its price hasn't moved much at all, with sub-2% gains. But short-term gains weren't the impetus behind the Buy rating on the stock anyway. It wasManika is a macroeconomist with over 20 years of experience in industries including investment management, stock broking, investment banking. She also runs the profile Long Term Tips [LTT], which focuses on the generational opportunity in the green economy. Her inves ...

Key Takeaways ALKS' alixorexton met primary goals in the phase II Vibrance-1 study for narcolepsy type 1. The 6 mg dose was the only one to meet a key secondary goal on cataplexy rates in the study. ALKS plans a global phase III trial as it eyes broader use of alixorexton in sleep disorders.Alkermes (ALKS) announced positive top-line data from the phase II Vibrance-1 study, which evaluated its novel, investigational, and oral orexin 2 receptor agonist, alixorexton (formerly ALKS 2680), for treating patien ...

Danaher (DHR) Q2 2025 Earnings Call July 22, 2025 08:00 AM ET Company ParticipantsJohn Bedford - VP - IRRainer Blair - President & CEOMichael Ryskin - Managing DirectorDoug Schenkel - MD - Life Science Tools & DiagnosticsMatt McGrew - EVP & CFOScott Davis - Chairman, CEO & Founding Partner – Multi-Industry ResearchTycho Peterson - Managing Director, Global EquitiesVijay Kumar - Senior MDPuneet Souda - Senior MDConference Call ParticipantsDan Leonard - MD & Research AnalystDaniel Brennan - Senior Equity Rese ...